Therapy Areas: Oncology
Novartis to acquire PI3K-alpha inhibitor program from Synnovation in deal worth up to USD3bn
20 March 2026 - Clinical-stage biotechnology company Synnovation Therapeutics LLC announced on Friday that Swiss pharmaceutical company Novartis AG (SIX:NOVN) (NYSE:NVS) has agreed to acquire Pikavati...
IBA and Telix partner to expand US radiopharmaceutical manufacturing capacity
20 March 2026 - Particle accelerator technology company Ion Beam Applications S.A. (IBA) (Euronext Brussels:IBAB) announced on Friday that it has signed a contract with Australian biopharmaceutical co...
Pfizer reports Phase 3 TALAPRO-3 results showing improved outcomes in metastatic prostate cancer
19 March 2026 - US biopharmaceutical company Pfizer Inc (NYSE:PFE) on Thursday announced positive topline results from the Phase 3 TALAPRO-3 study evaluating TALZENNA (talazoparib) in combination with...
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
19 March 2026 - Swedish life science tools company Mabtech announced on Wednesday a strategic collaboration with Sai Life Sciences, a global Contract Research Organisation (CRO).Under the agreement, S...
Samsung Bioepis partners with Sandoz on up to five next-generation biosimilars
18 March 2026 - South Korean biopharmaceutical company Samsung Bioepis Co Ltd on Wednesday announced a global development and commercialisation agreement with Sandoz Group AG (SIX:SDZ), a generics and...
Avacta opens Phase 1 trial for AVA6103 cancer therapy in US
16 March 2026 - Biopharmaceutical company Avacta Group plc (AIM:AVCT) reported on Monday that it has opened a Phase 1 clinical trial for FAP-Exd (AVA6103), its second pipeline programme and the first ...